Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies

Key Points The emergence of cancer immunotherapy has revolutionized cancer treatment but is associated with serious immune-related adverse effects (IRAEs) Cytotoxic T-lymphocyte antigen 4 (CTLA4)-targeted immunotherapy is associated with increased susceptibility to hypophysitis and primary thyroid d...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature reviews. Endocrinology Jg. 13; H. 4; S. 195 - 207
Hauptverfasser:	Byun, David J., Wolchok, Jedd D., Rosenberg, Lynne M., Girotra, Monica
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London Nature Publishing Group UK 01.04.2017 Nature Publishing Group
Schlagworte:	631/154/51/1568 692/163/2743/1279 692/163/2743/1841 692/163/2743/2742/1738 692/308/409 692/699/67/1059/2325 692/700/565/1436 Animals Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Cancer therapies Cancer treatment Complications and side effects CTLA-4 Antigen - biosynthesis Endocrine diseases Endocrine System Diseases - chemically induced Endocrine System Diseases - immunology Endocrine System Diseases - metabolism Endocrinology Enzyme inhibitors Humans Hyperthyroidism Hypothyroidism Immune system Immunotherapy Immunotherapy - adverse effects Ipilimumab Kinases Ligands Lymphocytes Medicine & Public Health Metastasis Monoclonal antibodies Neoplasms - drug therapy Neoplasms - immunology Neoplasms - metabolism Patients Programmed Cell Death 1 Receptor - biosynthesis Proteins review-article Risk factors T cell receptors United States > US
ISSN:	1759-5029, 1759-5037, 1759-5037
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!